Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.

Myasthenia Gravis | Image Credit: © lexiconimages-stock.adobe.com

MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe

By Maggie L. Shaw

April 1st 2025

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.

Rozanolixizumab Remains Consistently Safe, Effective for gMG

By Maggie L. Shaw

March 21st 2025

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat anti–acetylcholine receptor– and anti–muscle-specific kinase–positive generalized myasthenia gravis (gMG) in adult patients; administration is subcutaneous and takes approximately 15 minutes.

FDA approval | Image Credit: © Olivier Le Moal-stock.adobe.com

FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis

By Luke Halpern

March 15th 2025

The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.

Dysphagia | Image Credit: © Zerbor-stock.adobe.com

Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction

By Maggie L. Shaw

March 9th 2025

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.

<1 2 3 4 5 6

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions